APLM Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Apollomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.75 |
| 52 Week High | US$105.00 |
| 52 Week Low | US$6.50 |
| Beta | 1.07 |
| 1 Month Change | 6.21% |
| 3 Month Change | -27.13% |
| 1 Year Change | -88.11% |
| 3 Year Change | -99.02% |
| 5 Year Change | n/a |
| Change since IPO | -99.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| APLM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.5% | -3.8% | -2.7% |
| 1Y | -88.1% | -2.6% | 23.4% |
Return vs Industry: APLM underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: APLM underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| APLM volatility | |
|---|---|
| APLM Average Weekly Movement | 35.2% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: APLM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: APLM's weekly volatility has increased from 21% to 35% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 45 | Guo-Liang Yu | www.apollomicsinc.com |
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers.
Apollomics, Inc. Fundamentals Summary
| APLM fundamental statistics | |
|---|---|
| Market cap | US$10.75m |
| Earnings (TTM) | -US$57.11m |
| Revenue (TTM) | US$2.10m |
5.1x
P/S Ratio-0.2x
P/E RatioIs APLM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APLM income statement (TTM) | |
|---|---|
| Revenue | US$2.10m |
| Cost of Revenue | US$0 |
| Gross Profit | US$2.10m |
| Other Expenses | US$59.21m |
| Earnings | -US$57.11m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -51.80 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,718.37% |
| Debt/Equity Ratio | 16.9% |
How did APLM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 13:14 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Apollomics, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Timothy Moore | D. Boral Capital LLC. |
| Robert Burns | H.C. Wainwright & Co. |